goserelin Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
pituitary hormone-release stimulating peptides 1327 65807-02-5

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • goserelin
  • Decapeptide I
  • zoladex
  • goserelin acetate
A synthetic long-acting agonist of GONADOTROPIN-RELEASING HORMONE. Goserelin is used in treatments of malignant NEOPLASMS of the prostate, uterine fibromas, and metastatic breast cancer.
  • Molecular weight: 1269.43
  • Formula: C59H84N18O14
  • CLOGP: -2.86
  • LIPINSKI: 3
  • HAC: 32
  • HDO: 18
  • TPSA: 493.39
  • ALOGS: -4.48
  • ROTB: 33

Drug dosage:

DoseUnitRoute
0.13 mg implant

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 20 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 0.04 ┬ÁM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD

Approvals:

DateAgencyCompanyOrphan
Dec. 29, 1989 FDA ASTRAZENECA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Malignant neoplasm progression 535.84 21.33 236 6584 64690 46614552
Metastases to bone 456.99 21.33 148 6672 17328 46661914
Metastases to liver 339.76 21.33 122 6698 19463 46659779
Breast cancer metastatic 177.72 21.33 69 6751 13609 46665633
Breast cancer 154.26 21.33 91 6729 45427 46633815
Neutropenia 151.95 21.33 142 6678 143062 46536180
PIK3CA-activated mutation 139.35 21.33 29 6791 572 46678670
Metastases to lymph nodes 117.41 21.33 42 6778 6589 46672653
Metastases to skin 100.60 21.33 26 6794 1354 46677888
Metastases to lung 97.92 21.33 42 6778 10654 46668588
Neoplasm progression 94.67 21.33 55 6765 26628 46652614
Hot flush 81.26 21.33 60 6760 43457 46635785
Disease progression 80.61 21.33 82 6738 91218 46588024
Metastases to peritoneum 71.39 21.33 23 6797 2625 46676617
Metastases to spine 71.00 21.33 23 6797 2671 46676571
Metastases to central nervous system 70.81 21.33 34 6786 11187 46668055
Bone lesion 64.44 21.33 25 6795 4906 46674336
Drug ineffective 44.37 21.33 22 6798 677816 46001426
Metastases to pleura 44.33 21.33 13 6807 1083 46678159
Osteonecrosis of jaw 43.98 21.33 38 6782 34364 46644878
CYP3A4 polymorphism 43.49 21.33 8 6812 80 46679162
Abdominal lymphadenopathy 43.20 21.33 11 6809 539 46678703
Tumour marker increased 42.91 21.33 17 6803 3524 46675718
Pneumonitis 41.71 21.33 34 6786 28386 46650856
Breast cancer recurrent 41.27 21.33 17 6803 3894 46675348
Jaundice 41.27 21.33 34 6786 28811 46650431
Metastases to adrenals 40.74 21.33 11 6809 678 46678564
Merycism 39.50 21.33 8 6812 137 46679105
Adnexa uteri mass 39.06 21.33 10 6810 501 46678741
Bone disorder 38.21 21.33 28 6792 20005 46659237
Osteonecrosis 38.21 21.33 31 6789 25713 46653529
Osteolysis 36.83 21.33 14 6806 2598 46676644
Osteitis condensans 36.08 21.33 6 6814 31 46679211
Lymphadenopathy 34.94 21.33 33 6787 33455 46645787
Endometrial hyperplasia 34.82 21.33 10 6810 774 46678468
Breast cancer female 34.40 21.33 17 6803 5946 46673296
Lymphadenopathy mediastinal 34.15 21.33 13 6807 2421 46676821
Fibrous histiocytoma 34.09 21.33 9 6811 509 46678733
Amenorrhoea 33.29 21.33 19 6801 8876 46670366
Palmar-plantar erythrodysaesthesia syndrome 31.13 21.33 25 6795 20426 46658816
Arachnoid cyst 30.44 21.33 7 6813 222 46679020
Dermatitis 29.70 21.33 21 6799 14187 46665055
Carbohydrate antigen 15-3 increased 28.94 21.33 9 6811 915 46678327
Metastases to spinal cord 28.89 21.33 5 6815 34 46679208
Pleural disorder 28.44 21.33 8 6812 574 46678668
Neuropathy peripheral 28.35 21.33 49 6771 90844 46588398
Invasive ductal breast carcinoma 28.10 21.33 15 6805 6153 46673089
Invasive lobular breast carcinoma 27.67 21.33 8 6812 634 46678608
Pleural effusion 27.57 21.33 46 6774 82906 46596336
Metastases to ovary 27.51 21.33 7 6813 342 46678900
Leukopenia 26.97 21.33 41 6779 68302 46610940
Uterine leiomyoma 26.87 21.33 16 6804 8083 46671159
Uterine polyp 26.83 21.33 10 6810 1757 46677485
Cervical polyp 25.63 21.33 6 6814 206 46679036
Bone pain 24.23 21.33 32 6788 46858 46632384
Alanine aminotransferase increased 24.15 21.33 45 6775 88406 46590836
Bile duct stenosis 23.42 21.33 8 6812 1093 46678149
Musculoskeletal chest pain 23.13 21.33 20 6800 18086 46661156
Ocular icterus 22.86 21.33 11 6809 3629 46675613
Hepatic lesion 22.15 21.33 11 6809 3886 46675356
Bladder cancer 21.64 21.33 10 6810 3016 46676226
Bone marrow infiltration 21.45 21.33 6 6814 422 46678820

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Osteonecrosis of jaw 278.22 15.17 127 8709 18491 29925151
Prostatic specific antigen increased 192.26 15.17 86 8750 11918 29931724
Metastases to bone 166.90 15.17 73 8763 9585 29934057
Prostate cancer 114.25 15.17 77 8759 23880 29919762
Interstitial lung disease 112.53 15.17 112 8724 60085 29883557
Malignant neoplasm progression 109.19 15.17 120 8716 72167 29871475
Prostate cancer metastatic 106.42 15.17 44 8792 5023 29938619
Osteonecrosis 99.53 15.17 61 8775 16074 29927568
Hot flush 84.21 15.17 53 8783 14627 29929015
Osteomyelitis 60.12 15.17 43 8793 14638 29929004
Tooth extraction 42.51 15.17 23 8813 4788 29938854
Death 40.79 15.17 210 8626 357073 29586569
Blood testosterone increased 39.91 15.17 14 8822 1018 29942624
Pain in jaw 39.49 15.17 31 8805 12125 29931517
Osteitis 38.20 15.17 15 8821 1496 29942146
Bone disorder 37.79 15.17 24 8812 6717 29936925
Bone pain 36.57 15.17 36 8800 18990 29924652
Pituitary haemorrhage 36.45 15.17 9 8827 188 29943454
Pituitary tumour benign 34.83 15.17 12 8824 827 29942815
Contracted bladder 33.98 15.17 6 8830 20 29943622
Eosinophilic cystitis 33.13 15.17 6 8830 24 29943618
Hepatic function abnormal 32.28 15.17 50 8786 41895 29901747
Exposed bone in jaw 32.05 15.17 14 8822 1826 29941816
Hypocalcaemia 31.34 15.17 35 8801 21341 29922301
Haematuria 29.80 15.17 50 8786 44784 29898858
PO2 increased 26.76 15.17 9 8827 576 29943066
Device expulsion 26.17 15.17 6 8830 90 29943552
Gingivitis 25.25 15.17 14 8822 3056 29940586
Cancer pain 25.04 15.17 13 8823 2489 29941153
Bone sequestrum 24.78 15.17 9 8827 724 29942918
Arterial injury 23.78 15.17 7 8829 289 29943353
Gingival erythema 23.58 15.17 6 8830 142 29943500
Metastases to spine 23.37 15.17 12 8824 2246 29941396
Purulent discharge 23.33 15.17 13 8823 2866 29940776
Injection site haemorrhage 23.31 15.17 19 8817 7836 29935806
Ubiquinone decreased 22.98 15.17 4 8832 12 29943630
PCO2 decreased 21.78 15.17 10 8826 1466 29942176
Injection site haematoma 21.52 15.17 10 8826 1507 29942135
Blood alkaline phosphatase increased 20.76 15.17 35 8801 31452 29912190
Bone debridement 18.94 15.17 6 8830 318 29943324
Bone lesion 18.85 15.17 11 8825 2646 29940996
Toxicity to various agents 18.62 15.17 15 8821 177168 29766474
Sequestrectomy 18.30 15.17 6 8830 355 29943287
Haemoglobin decreased 18.05 15.17 74 8762 114024 29829618
Pulmonary embolism 17.72 15.17 57 8779 78078 29865564
Protein total decreased 17.04 15.17 13 8823 4872 29938770
Gingival swelling 16.90 15.17 8 8828 1256 29942386
Central nervous system mass 16.36 15.17 4 8832 80 29943562
Wall motion score index abnormal 16.18 15.17 4 8832 84 29943558
Airway remodelling 16.18 15.17 4 8832 84 29943558
Urinary retention 15.90 15.17 32 8804 32885 29910757

Pharmacologic Action:

SourceCodeDescription
ATC L02AE03 ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
ENDOCRINE THERAPY
HORMONES AND RELATED AGENTS
Gonadotropin releasing hormone analogues
FDA MoA N0000175654 Gonadotropin Releasing Hormone Receptor Agonists
FDA EPC N0000175655 Gonadotropin Releasing Hormone Receptor Agonist
MeSH PA D000970 Antineoplastic Agents
MeSH PA D018931 Antineoplastic Agents, Hormonal

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Endometriosis indication 129103003
Hormone receptor positive malignant neoplasm of breast indication 417181009
Advanced Prostatic Carcinoma indication
Endometrial Ablation Adjunct indication
Urinary tract obstruction contraindication 7163005 DOID:5200
Hypercholesterolemia contraindication 13644009
Hypertensive disorder contraindication 38341003 DOID:10763
Hypercalcemia contraindication 66931009 DOID:12678
Diabetes mellitus contraindication 73211009 DOID:9351
Hyperglycemia contraindication 80394007 DOID:4195
Pregnancy, function contraindication 289908002
Bilateral orchidectomy contraindication 386634006
Cardiovascular event risk contraindication 395112001
Breastfeeding (mother) contraindication 413712001
Obesity contraindication 414916001 DOID:9970
Smokes tobacco daily contraindication 449868002
Bone Metastases contraindication
Vertebral Metastases contraindication

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 8.85 acidic
pKa2 9.65 acidic
pKa3 11.9 acidic
pKa4 12.55 acidic
pKa5 13.03 acidic
pKa6 13.27 acidic
pKa7 13.43 acidic
pKa8 10.75 Basic
pKa9 6.69 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Gonadotropin-releasing hormone receptor GPCR AGONIST CHEMBL CHEMBL
Lutropin-choriogonadotropic hormone receptor GPCR WOMBAT-PK

External reference:

IDSource
N0000007256 NUI
D00573 KEGG_DRUG
145781-92-6 SECONDARY_CAS_RN
4019508 VANDF
C0120107 UMLSCUI
CHEBI:5523 CHEBI
CHEMBL1201247 ChEMBL_ID
CHEMBL1200501 ChEMBL_ID
DB00014 DRUGBANK_ID
D017273 MESH_DESCRIPTOR_UI
5311128 PUBCHEM_CID
3879 IUPHAR_LIGAND_ID
5943 INN_ID
0F65R8P09N UNII
203146 RXNORM
1550 MMSL
4799 MMSL
d01354 MMSL
003532 NDDF
006407 NDDF
008308 NDDF
008309 NDDF
108771008 SNOMEDCT_US
108773006 SNOMEDCT_US
126138002 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
ZOLADEX HUMAN PRESCRIPTION DRUG LABEL 1 50090-3466 IMPLANT 3.60 mg SUBCUTANEOUS NDA 26 sections
ZOLADEX HUMAN PRESCRIPTION DRUG LABEL 1 70720-950 IMPLANT 3.60 mg SUBCUTANEOUS NDA 26 sections
ZOLADEX HUMAN PRESCRIPTION DRUG LABEL 1 70720-951 IMPLANT 10.80 mg SUBCUTANEOUS NDA 26 sections